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Abstract. The aim of this study is to evaluate response of cervical cancer stage IB – IIA after neoadjuvant 
chemotherapy based on VEGF expression. The data were collected from 51 patients’ cervical cancer stage 
IB – IIA parafin blocks who received chemotherapy ifosfamide – cisplatin before radical hysterectomy at 
General Hospital Adam Malik Medan. VEGF expression was evaluated from cervical biopsy tissue, and 
response therapy was evaluated based on tumor size clinically. 20 out of 51 samples with clinically 
complete response, and the rest are partial response. 18 out of 20 samples with clinically complete response 
have negative or weak VEGF expression, and 31 out of 51 samples patients were partialy response with 
moderate or strong VEGF expression. 23 cases with tumor size > 4 cm and 23 cases stage IIA expressed 
VEGF moderately or strong. Cervical cancer with tumor size < 4 cm and cervical cenncer stage IB with 
less expressed of VEGF have good response with chemotherapy adjuvant ifosfamide – cis platin.Keyword: 
ifosfamide-cisplatin, cervical cancer, VEGF 
Abstrak. Penelitian ini bertujuan untuk menilai respon kemoterapi penderita kanker serviks stadium IB – 
IIA berdasarkan ekspresi VEGF. Bahan dan cara kerja: data diperoleh dari 51 blok parafin penderita 
kanker serviks stadium IB – IIA yang mendapat kemoterapi ifosfamid – cis platin sebelum menjalani 
operasi histerektomi radikal di RS H.Adam Malik Medan. Ekspresi VEGF dinilai dari jaringan biopsi 
sebelum pengobatan, dan respon kemoterapi dinilai berdasarkan ukuran tumor secara klinis. Respon 
komplit dijumpai pada 20 dari 51 penderita dan sisanya dengan respon parsial. 18 kasus respon komplit 
tidak atau lemah mengekspresikan VEGF, sementara 31 penderita respon parsial mengekspresikan VEGF 
sedang atau kuat.. 23 kasus dengan ukuran tumor ≥  4 cm dan 23 kasus stadium IIA mengekspresikan 
VEGF sedang atau kuat. Kemoterapi adjuvan ifosfamide – cis platin memberikan respon yang baik pada 
kanker serviks dengan ukuran lesi ≤ 4 cm dan stadium IB yang kurang mengekspresikan VEGF. Kata kunci: 
ifosfamide-cisplatin, kanker serviks, VEGF 
1. Introduction 
Cervical cancer  is the second commonest cancer in women after breast cancer in Indonesia. In 
2012, there were 20.928 new cases and 9.498 died because of cervical cancer. (1) 
Radiation and surgery are the basic treatments for cervical cancer depend on facilities, patient’s 
condition and the disease itself. (2) (3). Unfortunately, surgery for lesion > 4 cm still gives 
unsatisfactory result, whereas 50%-60% cases were not reach the radicality of surgery. (4) 
Mc Cann found that there are 63% cases which underwent radical hysterectomy with disease free 
of tumor at vaginal incision. (5) Almost 84% cases of cervical cancer stage IB- IIA with lesion > 
4 cm have to be radiated for adjuvant treatment after radical hysterectomy. (6) 
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Neoadjuvant chemotherapy could decrease recurrency risk factor and increase surgical radicality, 
and at the end could decrease the use of radiation after radical hysterectomy for early stage 
cervical cancer. (7) (8) 
Postponing surgery and neoadjuvant chemotherapy will still cause risk for the treatment result. 
Carefully choosing which neoadjuvant chemotherapy that would be benefit is essential.  
Choi et al. reported that there is a close relationship between VEGF expression and chemotherapy 
neoadjuvant response. Cervical cancer cases with high express VEGF have less response for 
chemotherapy neoadjuvant. (9) 
 
2. Methods 
Data were collected at Adam Malik Hospital Medan with immunohistochemistry staining for 
VEGF expression from parafin block of cervical biopsy tissue from cervical cancer patients with 
stage IB – IIA. The staining was done at Pathology Anatomy Department on January and February 
2017 for 51 parafin blocks of patients which received chemotherapy neoadjuvant from January 
2014 until January 2017. 
The chemotherapy regiment is a combination of ifosfamide and cisplatin intra venously that given 
for three weeks. 2000 mg/m2 ifosfamide was given at day 1,3 and 5, and 50 mg/m2 cis-platin at 
day 1. Mesna dose was 20% of ifosfamide dose at day 1,3 and 5. While day 2,4 and 6 mesna dose 
was 50% of ifosfamide dose. After three cycles chemotherapy all patients underwent radical 
hysterectomy. 
VEGF expression detected using Vascular Endothlial Growth Factor (VEGF) anti body, clone 
VG1, mouse anti human. VEGF expression interpretted by two patologists. The parafin block 
sliced 3-4 micrometer, heated at 37oC and 60oC. Deparafinization thrice with xylol and rehidrated 
with alcohol 90% and 80%. Then rinse with water and blocking endogen peroxiside and washed 
with phosphate buffered saline. After added with anti body primer, it washed again with 
phosphate buffered saline. Labelled with trekavidin-horseradish peroxydase, chromogen 3,3’-
diaminobenzadine and counter staining with hematocyclin. 
 
3. RESULTS. 
From January 2014 until January 2017 period, there were 75 cervical cancer patients stage IB –
IIA which treated with neoadjuvant chemotherapy. Unfortunately only 51 parafin blocks can be 
evaluated for VEGF expression. 
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Table.1. Clinicopathology characteristic and treatment response 
Age Complete Response Partial Response N 
≤ 40 year 1 4 5 
> 40 year 19 27 46 
Lesion size    
≤ 4 cm 19 9 28 
> 4 cm 1 22 23 
Hystology    
Squamous cell carsinoma 20 26 46 
Adenocarsinoma 0 5 5 
Differentiation    
Well 11 13 24 
Moderate 7 10 17 
Poor 2 8 10 
Stage    
IB 15 14 29 
IIA 5 17 22 
 
The responses of treatment were evaluated after three cycles neoadjuvant chemotherapy. 
Response was evaluated for tumor size clinically. 20 out of 51 cases with complete responses, 
while 31 cases with partial responses. In our center, the reason to give neodjuvant chemotherapy 
are to reach the surgical radicality, and long waiting list for surgery. All patients were given 
neoadjuvant chemotherapy. Partial response results were more often for cases with tumor size > 
4 cm, stage IIA and poor differentiation. 
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Table.2.VEGF expression for tumor size, stage and treatment response. 
Tumor size Negative  Weak Moderate Strong  p 
≤ 4 cm 4 14 10 0 0.005 
> 4 cm 0 0 18 5  
Stage      
IB 4 11 14 0 0.005 
IIA 0 3 14 5  
Treatment resonse      
Complete 4 14 2 0 0.005 
Partial 0 0 26 5  
 
There are strong relationship between VEGF expression, tumor size and stage. Partial response 
result was more often for tumor size > 4 cm, stage IIA with strong VEGF expresion. 
 
4. DISCUSSION. 
In this study, patient’s age were correspond with data from Information Centre on HPV and 
Globocan 2012, where the most cervical cancer patients were found at age more than 40 years 
old. (1) (10) 
When tumor size increases, many of its cells will fall in hypoxia condition. These hypoxic cells 
will activate antiapoptosis mediator for cell survival. In the other hand, hypoxia condition will 
activate HIF-1α and finally activate VEGF. But chemotherapy response were decreased in this 
case. (11) (12) 
In this study, VEGF expression was interpretted by two patologists, and the kappa test is 85.5%. 
Based on this kappa test where the two interpretter are equal, we used data from the first 
interpretter. 
From table 2, description of negative and weak VEGF expression which only found in tumor with 
≤ 4 cm size. The same condition was found for tumor with partial response. VEGF expression 
was not correlated with hystology type and differentiation. 
For tumor growth, angiogenesis process is very important. When the tumor cells are increasing, 
because of hypoxia condition, it will activate HIF-1α and induced neovasculazation. This new 
vascular walls is different from normal vascular wall, which is fragile, more permiable and twisted 
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in appearance. With this vascular characteristic, it will inhibit distribution of chemotherapy agent 
and decrease the chemotherapy response. (12) (13) (14) 
In this study we found that cervical cancer with strong VEGF expression showed  good 
chemotherapy response. 
 
5. CONCLUSION. 
Ifosfamide and cis-platin as neoadjuvant chemotherapy treatment for cervical cancer stage IB – 
IIA especially with large tumor size can shrink the tumor mass and make the radicality result of  
surgery become easier. Completed responses result more often in cervical cancer stage IB and 
tumor size < 4 cm whereas they express VEGF less.  
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